ALAB.NASDAQAstera Labs, INC

Form 4: Astera Labs CEO Transfers Shares to Living Trust

Sentiment:

Insider Transaction Report


Astera Labs CEO Jitendra Mohan transferred 559,230 shares of common stock to a living trust for estate planning purposes.

Summary

  • Jitendra Mohan, Chief Executive Officer and Director of Astera Labs, Inc. (ALAB), reported a change in beneficial ownership.
  • On December 1, 2025, Mr. Mohan transferred 559,230 shares of Astera Labs Common Stock to a living trust for no consideration.
  • Following this transaction, Mr. Mohan directly beneficially owns 1,521,188 shares of Common Stock.
  • Indirect beneficial ownership includes 4,689,232 shares held by the Living Trust, 699,999 shares by an estate planning Trust, 700,000 shares by 2021 Trust 1, 700,000 shares by 2021 Trust 2, 450,001 shares by 2022 Trust 1, and 450,001 shares by 2022 Trust 2.
  • Mr. Mohan disclaims beneficial ownership of the shares held by the trusts, except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: Neutral, as the filing reports a routine estate planning transaction by an insider, which does not directly impact the company's operational or financial performance.

Positives

  • The transaction represents a routine estate planning activity by a key executive, not a sale into the open market.
  • Significant insider ownership, both direct and indirect through trusts, remains, indicating continued alignment with shareholder interests.

Risks

  • The reporting person disclaims beneficial ownership of the securities held by the various trusts, except to the extent of any pecuniary interest, which could imply a nuanced view on control or economic interest for certain purposes.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Management Comments

  • Jitendra Mohan, as CEO and Director, executed a transfer of shares to a living trust for no consideration.
  • Mr. Mohan disclaims beneficial ownership of the securities held by the various trusts, except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing details an insider's personal estate planning transaction, which is a common practice among executives and does not directly reflect broader industry trends or competitive dynamics. It is an internal financial management event for the individual rather than a corporate strategic move.

Related Party Transactions

  • Transfer of 559,230 shares of Common Stock by the CEO to a living trust for no consideration.

Stakeholder Impact

  • Shareholders: Minimal direct impact as this is a non-market, internal transfer for estate planning purposes. It does not dilute existing shares or signal a change in company fundamentals.
  • Employees, Customers, Suppliers, Creditors: No direct impact from this personal financial transaction by the CEO.

Key Dates

DateDescription
12/01/2025Date of transaction where 559,230 shares of Common Stock were transferred to a living trust.
12/03/2025Date the Form 4 was signed and filed.

Recommendation

hold

This Form 4 filing details a personal estate planning transaction by Astera Labs' CEO, involving the transfer of shares to a living trust for no consideration. This is a routine and non-market event that does not provide new information regarding the company's operational performance, financial health, or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Astera Labs, ALAB, Jitendra Mohan, CEO, Form 4, beneficial ownership, stock transfer, living trust, estate planning, insider transaction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.